News & Views | Telix Pharmaceuticals Limited

Telix Pharmaceuticals and Eckert & Ziegler Sign German Distribution Agreement for Prostate Cancer Imaging

Telix has entered an exclusive commercial distribution agreement with Eckert & Ziegler for Telix’s prostate cancer imaging product Illuccix® for the German market.

Telix Pharmaceuticals Limited AGM 2021 – Chairman and CEO Addresses

Telix provides the Chairman’s Address and the CEO’s Presentation to the Annual General Meeting of Shareholders.

Telix and Monrol Expand Alliance to Include Lutetium Supply

Telix announces global clinical supply agreement with Monrol for the supply of no carrier added lutetium-177 for use in Telix’s MTR products.

Telix Announces Executive Leadership Appointments and Establishment of Asia Pacific Operating Region

Telix announces several key executive leadership appointments, including the establishment of an Asia-Pacific (APAC) operating region, further continuing the Company’s rapid commercial growth.

Telix Pharmaceuticals and Global Medical Solutions Complete Strategic Manufacturing Agreement

Telix announces it has completed a strategic manufacturing agreement with Global Medical Solutions to manufacture and supply finished unit doses of MTR products for clinical development programs.

Australian TGA Accepts Telix’s Prostate Cancer Imaging Product Submission and Commences Priority Evaluation Process

Telix announces the Australian Therapeutic Goods Administration has accepted its prostate cancer imaging product submission and commenced the priority evaluation process

Telix Pharmaceuticals Limited – Notice of Annual General Meeting 2021

Telix Pharmaceuticals provides notice of The Annual General Meeting of Shareholders on Wednesday 12 May 2021

Telix Pharmaceuticals and Grand River Aseptic Manufacturing Complete Agreement for Commercial Manufacturing of Illuccix®

Telix announces it has completed an agreement with Grand River Aseptic Manufacturing to perform GMP manufacturing of Telix’s prostate cancer imaging product.

Telix Pharmaceuticals and ITM Complete Global Agreements for Lutetium-177 Radioisotope Supply

Telix announces it has extended its non-exclusive global clinical and commercial supply agreements with Garching-based ITM AG

AUDIO LINK NOT INCLUDED – Telix Pharmaceuticals Releases Results for the Year Ended 31 December 2020 and 2020 Annual Report

Telix Pharmaceuticals Limited Releases Full-Year 2020 Results and 2020 Annual Report.